ERNAW Ernexa Therapeutics Inc. Warrants
$0.04▼ -11.52%
Unknown
Other
Volume 59.5K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.04 - 0.07
% vs 50 MA
-38.33%
% vs 200 MA
–%
RSI-14
43.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
8.89
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire · Aug 27, 2026 1:01 PM
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
GlobeNewswire · Jul 24, 2026 1:20 PM
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
GlobeNewswire · Jul 15, 2026 11:50 AM
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
GlobeNewswire · Jul 14, 2026 1:01 PM
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
GlobeNewswire · Jun 25, 2026 1:15 PM
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
GlobeNewswire · Jun 17, 2026 12:47 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for ERNAW.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.